Bokf Na Has $2.62 Million Position in Biogen Inc. $BIIB

Bokf Na reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 26.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 14,868 shares of the biotechnology company’s stock after selling 5,412 shares during the period. Bokf Na’s holdings in Biogen were worth $2,617,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. WPG Advisers LLC raised its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the period. First Horizon Corp purchased a new position in shares of Biogen during the 4th quarter valued at $30,000. GoalVest Advisory LLC purchased a new position in shares of Biogen during the 4th quarter valued at $35,000. Accredited Wealth Management LLC grew its holdings in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. Finally, Elevation Wealth Partners LLC grew its holdings in shares of Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 161 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Up 0.4%

BIIB stock opened at $191.38 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 1 year low of $115.25 and a 1 year high of $202.41. The company has a fifty day simple moving average of $184.27 and a 200 day simple moving average of $177.50. The firm has a market cap of $28.25 billion, a PE ratio of 20.53, a PEG ratio of 1.67 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the business earned $3.02 EPS. Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts anticipate that Biogen Inc. will post 14.31 EPS for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.18% of the company’s stock.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wolfe Research and Needham published multi‑year upside: Wolfe projects FY2027–FY2030 EPS rising to $17.59, $18.94 and $21.17 (FY30), signaling stronger long‑term growth expectations; Needham’s longer‑range numbers (FY2027–FY2030) are also above current consensus in some years. These upward longer‑term views support a constructive medium/long‑term thesis.
• Positive Sentiment: Canaccord Genuity reaffirmed a Buy on BIIB, providing some buy‑side support for the shares. Canaccord Genuity Sticks to Its Buy Rating for Biogen (BIIB)
• Neutral Sentiment: Barclays and BMO Capital both maintained Hold ratings on BIIB — this keeps a portion of the broker community neutral rather than adding downward pressure. Barclays Keeps Their Hold Rating on Biogen (BIIB) BMO Capital Reaffirms Their Hold Rating on Biogen (BIIB)
• Neutral Sentiment: An unrelated press item on Giant Biogene (HK:2367) appeared in feeds; it does not pertain to Biogen (BIIB) but may have cluttered news flow. Giant Biogene Sets 2026 AGM
• Negative Sentiment: Wolfe Research cut its Q2 2026 EPS estimate sharply (from $3.78 to $3.11), a near‑term downgrade that could pressure sentiment around upcoming quarterly performance.
• Negative Sentiment: Needham also slashed its Q2 2026 EPS estimate (from $4.40 to $2.90), another notable near‑term revision that increases uncertainty for the next reported quarter.

Analysts Set New Price Targets

Several equities analysts have recently commented on BIIB shares. The Goldman Sachs Group boosted their price target on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. Stifel Nicolaus boosted their price target on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Citigroup boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and an average price target of $214.23.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.